COVID-19 preclinical drug development database

Screening of Targeted Compounds - CVR

MRC - University of Glasgow Centre for Virus Research

Added 15/05/2020 | Updated 27/05/2020

Project Details

Type of project

  • Tier 1: repurposing existing medicines
  • Tier 2: testing existing molecules
  • Supporting technologies, models and assays

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)
  • Preventing virus replication in early disease
  • Direct acting antiviral

Type of supporting technology

  • Purified SARS-CoV-2 proteins
  • Engineered cells lines
  • Viral isolates
  • Assays and protocols (eg. for virus detection)

Phase of project

  • Focused compound screening (eg. known antiviral compounds)

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • Multiple Viral and Host Targets

Partner institutions/organisations

  • University of Dundee Drug Discovery Unit
  • Bill & Melinda Gates Foundation COVID-19 Therapeutics Accelerator

Key contact

Name: Sam J Wilson

Email Address: sam.wilson@glasgow.ac.uk

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

6-12 months

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*